Development of VLP vaccine for RSV

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI109926-02
Agency Tracking Number: R42AI109926
Amount: $1,867,924.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-18
Award End Date (Contract End Date): 2019-07-31
Small Business Information
9610 MEDICAL CENTER DR, Rockville, MD, 20850-3347
DUNS: 965180610
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JORGE BLANCO
 (301) 294-8619
 j.blanco@sigmovir.com
Business Contact
 JORGE BLANCO
Phone: (202) 322-0606
Email: j.blanco@sigmovir.com
Research Institution
 UNIV OF MASSACHUSETTS MED SCH WORCESTER
 55 LAKE AVENUE NORTH
WORCESTER, MA, 01655-0002
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Respiratory syncytial virus RSV is a substantial threat to human health most severely affecting three large populations infants young children and the elderly Despite the significance of RSV disease in these different populations there are no vaccines available The goal of this Phase II STTR project is to continue preclinical testing of a novel RSV vaccine candidate a candidate unlike any previously tested This candidate is a virus like particle VLP built on the Newcastle disease virus core proteins M and NP and containing the RSV A F and G proteins inserted into the membrane of the particle The objective is to determine the potential of VLPs as a vaccine for each of the human populations at risk for serious disease using well characterized cotton rats models as surrogates for these groups Specific aim Optimize protective responses in young animals Children from years of age comprise a substantial proportion of RSV illness burden and likely provide a reservoir for infection of newborns This age group is considered to have less safety constrains than the newborn month age group and is most likely the population where direct vaccination should be seriously considered Thus for use of VLPs as a vaccine for this population the immune responses in young animals will be optimized by testing different routes of VLP delivery and options for VLP formulations for cross protection from RSV B infections Specific aim Determine the efficacy of maternal immunization in protection of neonates Direct vaccination of neonates is likely ineffective due to the immaturity of their immune system safety concerns and inhibition of vaccine protection by maternal antibodies An alternative approach is protection of newborns from RSV infections through maternal vaccination that will enhance and extend passive transfer of maternal neutralizing antibodies to the fetus Thus the protection of cotton rat pups by VLP vaccination of na ve and RSV experienced mothers will be measured by virus titer in the pupsandapos lungs and nasal tissue after RSV challenge In addition safety of maternal immunization in offspring will be determined by measuring lung histology after RSV challenge of pups Specific aim Assess efficacy of VLP immunization in elderly populations Elderly immune systems are less vigorous than younger adult populations thus the responses to a vaccine candidate may be different than those of younger adults Furthermore the elderly population has experienced RSV infections in their lifetime Therefore the protection of both na ve and RSV experienced elderly cotton rats by different doses and routes of VLP immunization will be assessed by serum responses and virus titers in lungs after virus challenge to evaluate different strategies of vaccination in this populationPUBLIC HEALTH RELEVANCE Respiratory syncytial virus RSV is one of the most frequent causes of acute respiratory tract infection most severely affecting infants young children and the elderly However after decades of effort no vaccine exists to protect these populations from the virus This project will continue the preclinical development of a completely new RSV vaccine candidate a candidate unlike any previously tested The efficacy of this vaccine candidate in the most vulnerable populations will be tested using the cotton rat as surrogate model for the different targeted human populations The results of the study should provide key data to support future clinical trials of the vaccine safety and efficacy

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government